Blankenberg, S.* ; Salomaa, V.* ; Makarova, N.* ; Ojeda, F.* ; Wild, P.* ; Lackner, K.J.* ; Jørgensen, T.* ; Thorand, B. ; Peters, A. ; Nauck, M.* ; Petersmann, A.* ; Vartiainen, E.* ; Veronesi, G.* ; Brambilla, P.* ; Costanzo, S.* ; Iacoviello, L.* ; Linden, G.J.* ; Yarnell, J.* ; Patterson, C.C.* ; Everett, B.M.* ; Ridker, P.M.* ; Kontto, J.* ; Schnabel, R.B.* ; Koenig, W.* ; Kee, F.* ; Zeller, T.* ; Kuulasmaa, K.* ; BiomarCaRE Investigators (*)
Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium.
Eur. Heart J. 37, 2428-2437 (2016)
AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively. METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar. CONCLUSION: In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Biomarker For Cardiovascular Risk Assessment In Europe ; Cardiovascular Risk ; High-sensitivity Assayed Troponin I ; Monica Risk Genetics Archiving And Monograph ; Mortality; Coronary-heart-disease; Highly Sensitive Assay; C-reactive Protein; Glomerular-filtration-rate; Natriuretic Peptide; Prognostic Value; Vascular Events; Cardiac Events; All-cause; T Assay
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2016
Prepublished im Jahr
HGF-Berichtsjahr
2016
ISSN (print) / ISBN
0195-668X
e-ISSN
1522-9645
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 37,
Heft: 30,
Seiten: 2428-2437
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Oxford University Press
Verlagsort
Oxford
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Epidemiology (EPI)
POF Topic(s)
30202 - Environmental Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-504000-002
G-504090-001
Förderungen
Copyright
Erfassungsdatum
2016-05-19